Comparing antifungal drugs for a serious lung fungal infection
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This study compares different antifungal medicines to see which works best for a serious lung fungal infection called pulmonary mucormycosis. If you have this infection and haven't had too much prior treatment, you might be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need a confirmed or highly suspected lung infection caused by a fungus called mucormycosis.
- You must not have already had more than 5 days of amphotericin B (a common antifungal) for this infection.
- You cannot be allergic to azole antifungals or amphotericin B.
- You must not have severe liver damage, very high liver enzymes, heart failure, or be on a heart/lung bypass machine (ECMO).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two antifungal medications (liposomal amphotericin B and posaconazole or isavuconazole) to treat a serious fungal infection called mucormycosis in people with blood cancers like leukemia or lymphoma. The goal is to see if this combination is safe and works well.
This trial tests a stronger antifungal medicine (liposomal amphotericin B) for people with a serious fungal lung infection who also have liver problems. It aims to see if this treatment is safe and effective for ICU patients.
This trial studies two types of antifungal medicines (amphotericin B and azoles) to see which works better for people with invasive fungal disease. It aims to help doctors choose the safest and most effective treatment.
This study looks at how a medicine called L-AmB (a type of amphotericin B, used to treat fungal infections) works in patients who are on ECMO. The goal is to find the right dose for people in your situation.
This trial looks at how a specific antifungal medicine, called liposomal amphotericin B, given over a longer period, helps prevent serious fungal infections in people undergoing treatment for cancer or receiving a stem cell transplant. It may be an option if you are at high risk for these infections.
This study looks at how well liposomal amphotericin B works for treating serious fungal infections in people who have had an organ transplant. It aims to understand the treatment's effectiveness and safety in a real-world setting.
Hear when a new Pulmonary Mucormycosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.